Nautilus Biotechnology (NAUT) Projected to Post Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect Nautilus Biotechnology to post earnings of ($0.14) per share for the quarter.

Nautilus Biotechnology Price Performance

Shares of NAUT stock traded down $0.02 during trading hours on Friday, reaching $0.69. 272,183 shares of the company were exchanged, compared to its average volume of 108,100. Nautilus Biotechnology has a fifty-two week low of $0.66 and a fifty-two week high of $3.09. The stock's fifty day moving average is $1.00 and its two-hundred day moving average is $1.73. The company has a market cap of $86.84 million, a price-to-earnings ratio of -1.23 and a beta of 1.39.

Insider Activity at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 53,300 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,117,788 shares of the company's stock, valued at approximately $10,016,610.12. This represents a 0.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 40.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nautilus Biotechnology

An institutional investor recently raised its position in Nautilus Biotechnology stock. Bank of America Corp DE raised its position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 37.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,419 shares of the company's stock after purchasing an additional 13,363 shares during the period. Bank of America Corp DE's holdings in Nautilus Biotechnology were worth $83,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 50.71% of the company's stock.

Analysts Set New Price Targets

Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.